MEDICENNA THERAPEUTICS CORP (MDNA) Stock Price & Overview
NASDAQ:MDNA • CA58490H1073
The current stock price of MDNA is 0.157 USD. Today MDNA is down by -13.16%. In the past month the price decreased by -43.73%. In the past year, price decreased by -75.7%.
MDNA Key Statistics
- Market Cap
- 10.933M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.12
- Dividend Yield
- N/A
MDNA Stock Performance
MDNA Stock Chart
MDNA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MDNA. When comparing the yearly performance of all stocks, MDNA is a bad performer in the overall market: 96.13% of all stocks are doing better.
MDNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDNA. MDNA has a great financial health rating, but its profitability evaluates not so good.
MDNA Earnings
MDNA Forecast & Estimates
11 analysts have analysed MDNA and the average price target is 2.88 USD. This implies a price increase of 1735.48% is expected in the next year compared to the current price of 0.157.
MDNA Groups
Sector & Classification
MDNA Financial Highlights
Over the last trailing twelve months MDNA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 56.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.75% | ||
| ROE | -32.55% | ||
| Debt/Equity | 0 |
MDNA Ownership
MDNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.33 | 402.17B | ||
| AMGN | AMGEN INC | 16.52 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.59 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.77 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.37 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.71 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.72 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 341.2 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDNA
Company Profile
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Company Info
IPO: 2015-07-13
MEDICENNA THERAPEUTICS CORP
2 Bloor St W 7th Floor
TORONTO ONTARIO M4S 3E2 CA
CEO: Fahar Merchant
Employees: 18
Phone: 14166485555.0
MEDICENNA THERAPEUTICS CORP / MDNA FAQ
Can you describe the business of MEDICENNA THERAPEUTICS CORP?
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Can you provide the latest stock price for MEDICENNA THERAPEUTICS CORP?
The current stock price of MDNA is 0.157 USD. The price decreased by -13.16% in the last trading session.
Does MDNA stock pay dividends?
MDNA does not pay a dividend.
What is the ChartMill rating of MEDICENNA THERAPEUTICS CORP stock?
MDNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for MDNA stock?
MEDICENNA THERAPEUTICS CORP (MDNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
What is MEDICENNA THERAPEUTICS CORP worth?
MEDICENNA THERAPEUTICS CORP (MDNA) has a market capitalization of 10.93M USD. This makes MDNA a Nano Cap stock.